Market Research Report
Europe Glucose Monitoring System Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||429442|
|Published||Content info||140 Pages
Delivery time: 2-3 business days
|Europe Glucose Monitoring System Market Forecast 2019-2027|
|Published: June 10, 2019||Content info: 140 Pages||
The Europe Continuous Glucose Monitoring System (CGMS) market is expected to rise from $XX million in 2018 to $XX million by 2027, exhibiting a CAGR of 32.91% over the forecast period of 2019-2027.
The Europe Self-Monitoring of Blood Glucose (SMBG) market is expected to rise from $XX million in 2018 to $XX million by 2027, at a CAGR of 5.42% over the forecasted period.
The number of diabetic patient pool in the European regional market have increased tremendously over the past few years. This, in turn, increased the need for awareness amongst the people about the advanced CGM devices to monitor glucose levels and manage insulin delivery. Also, there was a need for improvement of health infrastructure for the same. Each of the 28 countries in Europe has its own system for approval of distributing and supplying medical devices. The German market dominated the European scene in 2018. However, the French market is expected to rise with the highest CAGR over the forecast period. This is due to the French's health infrastructure and services being one of the best in the world.
Companies like Abbott, Senseonics Inc., Terumo, GlySens Inc., Tandem Diabetes Care, Medtronic, Morepen Laboratories Ltd., B Braun Melsungen AG, Becton Dickinson And Company, Dexcom, Wockhardt, Ypsomed, I-Sens Inc., Nemaura Medical Inc., Insulet Corp., ARKRAY Inc., Roche Diagnostics, Apex Biotechnology Corp., Johnson and Johnson, and Ascensia are leading in this region.